SRR17866851
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 41.1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.440
- MITOTIC_SPINDLE+0.390
- HEDGEHOG_SIGNALING+0.350
- TNFA_SIGNALING_VIA_NFKB+0.340
- TGF_BETA_SIGNALING+0.320
- WNT_BETA_CATENIN_SIGNALING+0.310
- HEME_METABOLISM+0.300
- PROTEIN_SECRETION+0.300
- G2M_CHECKPOINT+0.290
- ESTROGEN_RESPONSE_EARLY+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.510
- MYC_TARGETS_V2-0.350
- DNA_REPAIR-0.340
- MYC_TARGETS_V1-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- ANGIOGENESIS-0.230
- ADIPOGENESIS-0.190
- FATTY_ACID_METABOLISM-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
- XENOBIOTIC_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-5249-01A-01R-1514-07 | — | — | 0.733 |
| 2 | TCGA-CR-6471-01A-11R-1873-07 | — | — | 0.732 |
| 3 | MNG670 | — | — | 0.719 |
| 4 | TCGA-22-1011-01A-01R-0692-07 | — | cohortSQ1 | 0.719 |
| 5 | SRR934773 | — | — | 0.701 |
| 6 | MNG435 | — | — | 0.699 |
| 7 | d719788d-0c64-4488-bb84-ab5536d31a03 | — | — | 0.691 |
| 8 | MNG454 | — | — | 0.687 |
| 9 | TCGA-CV-7427-01A-11R-2081-07 | — | — | 0.680 |
| 10 | 20ca78ce-1972-4f55-81f2-22683da33c66 | — | — | 0.678 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.440 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |